Evercore ISI Upgrades Bausch & Lomb Corp. (BLCO) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Wells Fargo Reiterates Overweight Rating on Bausch & Lomb Corp. (BLCO)
October 15, 2024 6:16 AM EDTWells Fargo analyst Larry Biegelsen reiterated an Overweight rating and $23.00 price target on Bausch & Lomb Corp. (NYSE: BLCO).
The analyst comments "What happened? According to the Financial Times (FT), Blackstone and TPG Capital are reportedly evaluating a potential joint bid for BLCO. The FT article also noted that other... More
TPG, Blackstone (BX) Team Up to Bid for Bausch + Lomb Corporation (BLCO) - FT
October 14, 2024 8:53 AM EDT(Updated - October 14, 2024 8:55 AM EDT)
TPG, Blackstone (NYSE: BX) Team Up to Bid for Bausch + Lomb Corporation (NYSE: BLCO) - FT
The report cites people familiar with the matter.Several other PE funds... MoreBausch + Lomb Corporation (BLCO) Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens
October 14, 2024 7:01 AM EDTBausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista® Envy full range of vision intraocular lens (IOL), which offers a continuous range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform.
Were confident that U.S. surgeons will agree with what their Canadian colleagues have already told us: enVista Envy delivers exceptional outcomes and meets cataract patients high expectations, as well as their... More
